XORI (chore-ee) Corporation will focus on a unique technology for the rapid discovery and development of monoclonal antibodies (MAbs). XORI will validate the technology on a variety of targets and develop superior products for cancer therapy, immune disorders, and infectious diseases. XORI was founded by Dr. Nancy Maizels, a professor in the Immunology and Biochemistry Departments and also Director of the Molecular Medicine Program at the University of Washington. Dr. Maizels’ laboratory has developed a proprietary technology for the rapid evolution of monoclonal antibodies. This new technology enables the evolution and selection of high affinity antibodies specific for virtually any target. XORI will be able to identify high affinity monoclonal antibodies within a matter of weeks, as opposed to the more traditional methods which require many months and often fail to generate high quality reagents.
Dr. Larry Tjoelker, formerly at ICOS, MacroGenics, and Spaltudaq, will join XORI as Senior Director of Research. Dr. Tjoelker received his Ph.D. in Craig Thompson’s lab at University of Pennsylvania, where he studied gene rearrangement and diversification in avian T and B cells. He was at ICOS for 11 years as Scientist and Senior Scientist. Dr. Tjoelker has focused on discovery of cancer targets for monoclonal antibody therapy as Scientific Director at MacroGenics for four years and at Spaltudaq for the past year.